SCHEMBL4846424

SCHEMBL4846424

Cc1ccc(-c2cccc3sc(N)nc23)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
SMN1; SMN2 Q16637 4/20 0.51
LMNA P02545 3/20 0.51
PDPK1 O15530 1/20 0.51
PDE10A Q9Y233 1/20 0.51
CYP3A4 P08684 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
XBP1 P17861 1/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
RAB9A P51151 2/20 0.44
HSD17B10 Q99714 1/20 0.44
ENPP1 P22413 1/20 0.43
GAA P10253 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
MYC P01106 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1806582 0.85 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2LMNAPDPK1PDE10A
SCHEMBL4848399 0.84 SMN1; SMN2 (0.51) ALDH1A1SMN1; SMN2LMNAPDPK1PDE10A
SCHEMBL4850036 0.83 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2LMNAPDPK1PDE10A
SCHEMBL4846229 0.81 PDPK1 (0.49) ALDH1A1SMN1; SMN2LMNAPDPK1PDE10A
SCHEMBL4916103 0.81 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2LMNAPDPK1PDE10A
SCHEMBL4843130 0.80 SMN1; SMN2 (0.51) ALDH1A1SMN1; SMN2LMNAPDPK1PDE10A
SCHEMBL12637464 0.78 ENPP1 (0.42) ALDH1A1SMN1; SMN2LMNACYP3A4MAPT
SCHEMBL22833973 0.78 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2LMNAPDPK1PDE10A
SCHEMBL30818053 0.78 MGAM (0.51) ALDH1A1SMN1; SMN2LMNAPDPK1PDE10A
SCHEMBL29992706 0.75 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2LMNAPDPK1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7390907-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2008-06-24 US disclosed
EP-1670794-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS Amgen Inc. (US) 2006-06-21 EP disclosed
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-07-14 US disclosed
WO-2005033105-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153984-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 ALDH1A1 3253/4885SMN1; SMN2 2664/4885LMNA 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.